SNTI — Senti Biosciences Share Price
0.000.00%
Last trade - 00:00- $86.33m
- $38.16m
- 27
- 21
- 80
- 38
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.7 | ||
| Price to Tang. Book | 1.7 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -72.07% | ||
| Return on Equity | -89.73% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.57 | 2.76 | 4.29 | 2.56 | n/a | 5 | 3.8 | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Senti Biosciences, Inc. is a clinical-stage biotechnology company. It is developing cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. It is focused on off-the-shelf CAR-NK cell therapy programs for oncology indications. Its lead product candidate, SENTI-202, is a potential Logic Gated off-the-shelf CAR-NK cell therapy designed to selectively target and eliminate CD33 and/or FLT3 expressing hematologic malignancies, including acute myeloid leukemia, while sparing healthy bone marrow cells. Its second clinical development program is SENTI-301A, a multi-armed off-the-shelf healthy donor derived CAR-NK cell therapy. SENTI-202 has been designed to incorporate three chimeric proteins using a Logic Gated gene circuit and delivered through a single retrovirus. SENTI-301A is a multi-armed off-the-shelf healthy donor derived CAR-NK cell therapy designed for the treatment of advanced GPC3 positive tumors.
Directors
- Omid Farokhzad CHM (52)
- Mostafa Ronaghi CEO (52)
- Mark Afrasiabi CFO (45)
- Rowan Chapman OTH (50)
- David Epstein IND (59)
- Jay Flatley IND (69)
- Deep Nishar IND (52)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- March 1st, 2021
- Public Since
- May 26th, 2021
- No. of Shareholders
- 69
- No. of Employees
- 34
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 26,004,366
- Address
- 2 Corporate Drive, First Floor, SOUTH SAN FRANCISCO, 94080
- Web
- https://www.sentibio.com/
- Phone
- +1 6503823281
- Auditors
- KPMG LLP
Upcoming Events for SNTI
Q1 2025 Senti Biosciences Inc Earnings Release
Senti Biosciences Inc Annual Shareholders Meeting
Q2 2025 Senti Biosciences Inc Earnings Release
Similar to SNTI
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Senti Biosciences share price?
As of Today at 23:10 UTC, shares in Senti Biosciences are trading at $3.32. This share price information is delayed by 15 minutes.
How has the Senti Biosciences share price performed this year?
Shares in Senti Biosciences last closed at $3.32 and the price had moved by -9.95% over the past 365 days. In terms of relative price strength the Senti Biosciences share price has underperformed the S&P500 Index by -18.8% over the past year.
What are the analyst and broker recommendations for Senti Biosciences?
The overall consensus recommendation for Senti Biosciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Senti Biosciences dividend yield?
Senti Biosciences does not currently pay a dividend.
Does Senti Biosciences pay a dividend?
Senti Biosciences does not currently pay a dividend.
When does Senti Biosciences next pay dividends?
Senti Biosciences does not currently pay a dividend.
How do I buy Senti Biosciences shares?
To buy shares in Senti Biosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Senti Biosciences?
As of the previous close price of $3.32, shares in Senti Biosciences had a market capitalisation of $86.33m.
Where are Senti Biosciences shares listed?
Here are the trading details for Senti Biosciences:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: SNTI
What kind of share is Senti Biosciences?
Based on an overall assessment of its quality, value and momentum Senti Biosciences is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Senti Biosciences share price forecast for 2025?
The analyst consensus target price for shares in Senti Biosciences is $12.00. That is 261.45% above the last closing price of $3.32.
Analysts covering Senti Biosciences currently have a consensus Earnings Per Share (EPS) forecast of -$1.88 for the next financial year.
Find out moreWhat is the trend in the Senti Biosciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Senti Biosciences. Over the past six months, its share price has outperformed the S&P500 Index by +52.99%.
As of the last closing price of $3.32, shares in Senti Biosciences were trading +1.94% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Senti Biosciences PE Ratio?
The Senti Biosciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.32.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Senti Biosciences?
Senti Biosciences' management team is headed by:
- Omid Farokhzad - CHM
- Mostafa Ronaghi - CEO
- Mark Afrasiabi - CFO
- Rowan Chapman - OTH
- David Epstein - IND
- Jay Flatley - IND
- Deep Nishar - IND